GlassScriptPhysician profile
Luann Evert
NPI 1659536530
$1,960.96
in general payments reported to CMS, 2019-2025
18 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $212 · 2023: $574 · 2024: $683 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $317.39 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $300.69 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $247.84 | 2021-2025 | Verquvo |
| Amgen INC. | $160.41 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $151.04 | 2021-2025 | Resonate El Icd Vr, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.10 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $128.18 | 2022-2024 | Farxiga |
| Pfizer INC. | $104.39 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $85.23 | 2021-2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $79.52 | 2023-2024 | Optimizer, Optimizer |
| Medtronic, INC. | $56.11 | 2021-2024 | Endurant Iis |
| Actelion Pharmaceuticals US, INC. | $36.90 | 2021-2023 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $35.93 | 2023 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $30.71 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $29.64 | 2025 | Evkeeza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $20.57 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $14.22 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $14.09 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luann Evert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.